Evoq Remedies Ltd
Evoq Remedies H1 FY2025 Results: Revenue at ā¹2,656.82 Lakhs, Net Profit ā¹5.43 Lakhs š
- Total Revenue for H1 FY2025: ā¹2,656.82 lakhs (Operations: ā¹2,550.68 lakhs, Other Income: ā¹106.14 lakhs)
- Profit Before Tax: ā¹7.88 lakhs; Net Profit: ā¹5.43 lakhs
- Shareholders' Funds: ā¹4,459.04 lakhs (Share Capital: ā¹2,490.00 lakhs, Reserves & Surplus: ā¹1,969.04 lakhs)
- Current Assets: ā¹5,201.83 lakhs (Short-Term Loans & Advances: ā¹3,265.50 lakhs, Trade Receivables: ā¹439.04 lakhs)
- SEBI summons received (July 2024) regarding financial statements; Show Cause letter (Nov 2024) on ā¹19.21 crore preferential allotment utilization
- Non-compliance with Companies Act (Section 178(5)) for audit trail software
- Advances to suppliers (ā¹1,250.87 lakhs) pending confirmation
- GST order (ā¹655.03 lakhs for FY 2017-18) under litigation
- Income tax provision (ā¹1.99 lakhs) and disputed demand (ā¹39.99 lakhs) under litigation
- Debtors outstanding (ā¹73.25 lakhs, mostly related parties) pending reconciliation
- Unpaid TDS/TCS: ā¹38.23 lakhs
- Short-term loans include ā¹668.86 lakhs to related parties with Companies Act non-compliance (Sections 177, 185, 186, 188, 189)